2020
Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination
Chuang YM, Dutta NK, Gordy JT, Campodónico VL, Pinn ML, Markham RB, Hung CF, Karakousis PC. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination. Frontiers In Immunology 2020, 11: 680. PMID: 32411131, PMCID: PMC7198710, DOI: 10.3389/fimmu.2020.00680.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, BacterialAntitubercular AgentsBacterial ProteinsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell LineChronic DiseaseDrug Resistance, BacterialFemaleGuanosine PentaphosphateGuinea PigsHydrolasesIsoniazidLigasesMacrophagesMiceMice, Inbred C57BLMycobacterium tuberculosisTreatment OutcomeTuberculosisTuberculosis VaccinesVaccinationVaccines, DNAConceptsTherapeutic vaccinationDNA vaccineT cellsC57BL/6 miceMtb persistersGuinea pigsAntigenic environmentFirst-line anti-TB drugsChronic TB infectionDrug-susceptible tuberculosisLung bacterial burdenAnti-TB drugsSpleens of miceHartley guinea pigsActivity of isoniazidAntitubercular treatmentReactive CD4Reactive CD8TB chemotherapyTB infectionTB treatmentCurrent regimenDaily dosesBacterial burdenIsoniazid treatment
2018
Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice
Chuang YM, Pinn ML, Karakousis PC, Hung CF. Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice. Frontiers In Cellular And Infection Microbiology 2018, 8: 31. PMID: 29473022, PMCID: PMC5809501, DOI: 10.3389/fcimb.2018.00031.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphatasesAdministration, IntranasalAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsBCG VaccineCD4-Positive T-LymphocytesCross ReactionsCytokinesDisease Models, AnimalFemaleImmunity, MucosalImmunizationLymphocyte DepletionMiceMolecular ChaperonesMycobacterium tuberculosisNasal MucosaTuberculosisTuberculosis VaccinesConceptsBacillus Calmette-GuérinIntranasal vaccinationT cellsMucosal immunityProtective immunityVaccine candidatesTissue-resident CD4Different immune statusProtective mucosal immunityNew vaccine candidatesGlobal health challengeResident CD4BCG vaccinationIntranasal immunizationMtb infectionImmune statusImmunocompetent miceDNA vaccineBCG vaccineC57BL/6J miceCalmette-GuérinAvailable vaccinesImmunocompromised individualsLimited efficacyCD4